Could the CSL share price be set for a boost before the year's end?

The CSL share price has been sluggish all year. Could a new drug treatment for haemophilia B turn things around?

| More on:
A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL shares have been sluggish all year and are down again today 
  • The company is developing a gene therapy to treat haemophilia B
  • The treatment is in Phase III and could be released to the market before the year is out if it gets approval from the US Food and Drug Administration

The CSL Limited (ASX: CSL) share price is in the red today, down 0.42% at the time of writing to $281.83.

CSL shares have been sluggish in recent times, down 5.1% in the past month and down 5.2% overall in 2022.

The company hasn't announced any price-sensitive news since its FY22 results on 17 August. But there have been some good developments in the CSL lab of late, as reported by The Age today.

New drug could boost earnings

EtranaDez is a gene therapy that CSL is developing to treat haemophilia B.

Patients with haemophilia B don't have the blood clotting protein Factor-IX. According to the article, EtranaDez instructs the patient's cells to produce Factor-IX, thereby negating the need for regular and time-consuming intravenous treatments.

The drug is currently in Phase III of its development. According to the article, the US Food and Drug Administration is expected to decide whether to approve the drug later this year.

CEO Paul Perreault hopes to put EtranaDez into the market before the year is out.

Whether this could boost the CSL share price remains to be seen.

What do the experts think?

The Institute for Clinical and Economic Review (ICER) has just published a draft report on the potential financial benefits of EtranaDez for CSL.

The ICER assumes a "placeholder price" of $2.5 million in the United States market.

In a note to clients, Wilsons analyst Dr Shane Story said the report "frames the potential benefit of a one-time prophylactic injection which could stabilise the [haemophilia B] for years".

The Wilsons equities team says the drug will enhance CSL's existing haemophilia treatments. It expects "at least 10 per cent in incremental share from the currently underserved young adult patient segment".

Macquarie and Credit Suisse analysts think EtranaDez will benefit CSL's earnings pipeline into 2024.

In a note to clients, Credit Suisse said it forecasts "peak sales of $US400 million with $US200 million upside to CSL's FY34 earnings".

CSL began developing the drug in a $655 million partnership with the NASDAQ-listed genomic medicine company UniQure in 2020.

A quick history on the CSL share price

Before the pandemic hit the ASX, the CSL share price was as high as $336.40 in February 2020. It came crashing down with the rest of the market to an initial low of $270.88 in March 2020.

Since then, CSL shares have been rangebound between the mid-$200s and about $315.

The CSL share price has not risen above $300 since December 2021.

Should you invest $1,000 in CSL right now?

Before you buy CSL shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 6 March 2025

Motley Fool contributor Bronwyn Allen has positions in CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man with a wide, eager smile on his face holds up three fingers.
Healthcare Shares

3 reasons to buy this surging ASX All Ords healthcare share today

A top expert forecasts more outperformance from this rocketing ASX healthcare stock.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Down 11% in 2025, are CSL shares a good buy right now?

Are CSL shares likely to go up from here?

Read more »

Three healthcare workers look and point at at medical image
Healthcare Shares

Pro Medicus to buyback 10.4 million shares. What does this mean?

Is this a sign to buy?

Read more »

A elder man and woman lean over their balcony with a cuppa, indicating share rpice movement for ASX retirement shares
Healthcare Shares

Why I think this ASX small-cap stock is a bargain at 40 cents

Here’s why this business has a compelling outlook...

Read more »

Two doctors give the thumbs up to an x-ray
Healthcare Shares

One likely reason the market has soured on Pro Medicus

Is there opportunity for brave investors?

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Hedge the rise in your health insurance premium with these 2 ASX stocks

Sick of price rises? Get on the other side of the transaction.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

2 ASX 200 biotech stocks announcing big news today

Let's see how the market has responded to these announcements.

Read more »

Happy man holding Australian dollar notes, representing dividends.
Healthcare Shares

This ASX 200 stock is rocketing 17% after announcing a $300m special dividend

A huge dividend is expected to be paid to investors in the near future.

Read more »